In addition, the α1-AR/TG2-mediated signaling pathway induced the expression of GD3S and GD3, resulting in K562 cell differentiation into the erythroid lineage due to GD3 interacting with α1-AR/TG2, which provided a new therapeutic target for CML (Ha et al., 2017). This evidence concerns the gene TGM2 and chronic myelogenous leukemia, BCR-ABL1 positive.